HC Wainwright Forecasts Altimmune’s Q4 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT) – Analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for Altimmune in a report issued on Monday, March 16th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.

Several other research analysts have also weighed in on ALT. B. Riley Financial dropped their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Barclays initiated coverage on shares of Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target on the stock. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.20.

Altimmune Price Performance

NASDAQ ALT opened at $3.62 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a market capitalization of $470.85 million, a price-to-earnings ratio of -3.58 and a beta of 0.13. The company has a 50 day simple moving average of $4.49 and a 200-day simple moving average of $4.30. Altimmune has a 52-week low of $2.90 and a 52-week high of $7.73.

Insiders Place Their Bets

In related news, Director John Gill bought 12,500 shares of the business’s stock in a transaction on Tuesday, December 23rd. The shares were bought at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $51,250. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jerome Benedict Durso purchased 20,000 shares of Altimmune stock in a transaction on Friday, March 6th. The stock was bought at an average cost of $3.54 per share, with a total value of $70,800.00. Following the transaction, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 55,527 shares of company stock valued at $213,778 over the last quarter. 4.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Arax Advisory Partners lifted its holdings in Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock worth $29,000 after purchasing an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in Altimmune by 27.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after purchasing an additional 1,928 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Altimmune in the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. acquired a new stake in shares of Altimmune in the third quarter worth $38,000. Finally, CreativeOne Wealth LLC acquired a new stake in shares of Altimmune in the fourth quarter worth $38,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.